SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending following an official determination from NOAA that its deep-seabed mining application is in full compliance, a key milestone that clarifies the regulatory path toward commercial operations. Community members are actively debating the significance of this news for long-term permitting and discussing whether the stock is positioned for a sustained rally despite recent volatility.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings Inc. (CELH) is experiencing extreme volatility as shares touch new 52-week lows, fueling intense community debate regarding institutional manipulation versus fundamental concerns like competition from private-label alternatives. Investors are closely monitoring the upcoming earnings release, with many split between those expecting a massive post-earnings rebound and those fearing further downside due to inventory and margin pressures.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant retail and institutional interest, fueled by a positive feature in the Wall Street Journal and community enthusiasm surrounding the company's expanding role in physical AI, robotics, and its QNX software platform. Investors are closely monitoring volume and price action as the community discusses potential breakouts, institutional accumulation, and the stock's long-term growth potential in cybersecurity and automotive technology.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending after announcing a strategic manufacturing partnership with Cellipont Bioservices to advance its ERNA-101 ovarian cancer therapy toward clinical trials. While some investors are excited by the potential for a short squeeze given the stock's low float and high volume, others remain skeptical, citing concerns over historical dilution and the speculative nature of early-stage biotech.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubo is experiencing significant volatility as retail investors debate the company's long-term viability and the impact of its partnership with Disney, while the stock faces heavy short interest and skepticism regarding management's profitability targets. The community remains deeply polarized, with bulls pointing to potential strategic synergies and oversold conditions, while bears cite historical subscriber losses and a lack of insider buying as reasons to avoid the stock.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense retail speculation as the community positions itself for upcoming earnings, with bulls betting that new management's strategic shift will trigger a parabolic move. Investors are actively debating the potential for a short squeeze, bolstered by optimism around housing market trends and aggressive accumulation of shares ahead of the official report.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging following an earnings report that emphasized improved profit margins and robust AI infrastructure demand, helping to alleviate concerns regarding recent legal and regulatory overhangs. Investors and community members are actively debating the company's valuation gap compared to sector peers and monitoring whether this momentum can sustain a potential short squeeze.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility and community debate as investors weigh the company's recent siRNA pipeline updates and Elevidys revenue growth against ongoing regulatory scrutiny and analyst skepticism regarding clinical data. The stock is currently a major focus for traders discussing potential short-squeeze dynamics and the long-term outlook for its Duchenne muscular dystrophy gene therapy franchise.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is facing significant volatility following its latest earnings report, where strong revenue growth and raised guidance are being offset by concerns regarding supply chain constraints and margin pressure. Despite the post-earnings sell-off, the community remains divided between those viewing the pullback as a buying opportunity given the firm's critical role in the AI data center buildout and those concerned that the stock's high valuation leaves it vulnerable to further correction.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is seeing high volatility and intense social media discussion as investors debate its valuation ahead of upcoming earnings, with bull-case optimism centering on potential government contracts and strategic acquisitions while bears express concerns over cash burn and dilution. Traders are heavily focused on the stock's recent price swings and potential for a short squeeze, leading to a highly polarized community dialogue regarding the company's long-term quantum computing prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>CEO Ng George K bought 2,136 shares of the company for a total purchase value of about $5415, the filing shows.</li><li>Overall, all the insiders cumulatively bought 16,175 shares of the company for a total purchase value of about $40,000.&nbsp;</li><li>Processa develops drugs for life-threatening and life-compromising chronic diseases.</li></ul>Shares of Processa Pharmaceuticals, Inc. (PCSA) closed up 6% and edged up 10% after hours on Thursday after several insiders at the company, including the CEO, made share purchases.According to filings made with the Securities and Exchange Commission, several insiders including Director Baluch Khoso, Chief Development Officer Bigora Sian, Chief Administrative Officer Guy Wendy, Chief Business Strategy Officer Lin Patrick, Chief Executive Officer Ng George K, Director Pannu Geraldine, Chief Financial Officer Skibsted Russell, President of Research &amp; Development Young David all bought shares of the company at a price of about $2.535 on the last day of March.CEO Ng George K bought 2,136 shares of the company for a total purchase value of about $5415, the filing shows. Overall, all the insiders cumulatively bought 16,175 shares of the company for a total purchase value of about $40,000.<h2 class="st-heading-2">About Processa</h2>Processa develops drugs for life-threatening and life-compromising chronic diseases. Its pipeline includes NGC-Cap and NGC-Iri for the treatment of certain cancers, PCS12852 for gastroparesis and constipation disorders and PCS499 for primary glomerular diseases. While the company has completed early-to-mid stage studies for PCS12852 and PCS499, mid-stage trials are in process for NGC-Cap. NGC-Iri, meanwhile, is still in preclinical stages.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PCSA stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.“Nice to see the little token insider purchases apparent "ploy" working just as designed. Predictable, like death and taxes,” a Stocktwits user wrote.<stembedurl>https://www.stocktwits.com/Jwa68/message/649316897</stembedurl>Another voiced optimism for the stock rallying up to $20.<stembedurl>https://www.stocktwits.com/Shallu/message/649328642</stembedurl><a href="https://stocktwits.com/symbol/PCSA">PCSA stock</a> has lost nearly 63% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lpcn-stock-crashes-heres-why/cZ7x6c9RI88">LPCN Stock Crashes 78%— Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

PCSA Stock Rallies 10% After Hours— Here’s Why

According to filings made with the Securities and Exchange Commission, several insiders bought shares of the company at a price of about $2.535 on the last day of March. 

Equity

According to filings made with the Securities and Exchange Commission, several insiders bought shares of the company at a price of about $2.535 on the last day of March. 


PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study

Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Processa Pharmaceuticals' stock jumps after Phase 2 data show higher capecitabine exposure without added toxicity in metastatic breast cancer patients.read more...

<ul class="summary-bullets"><li>Hut 8 shares were up more than 11% in Wednesday’s midday trade after the company announced that it is building an AI data center for Anthropic.</li><li>Processa Pharmaceuticals' shares were up nearly 95% after early Phase 2 data showed that its NGC-Cap therapy boosts capecitabine exposure without added side effects compared with standard treatment.</li><li>Recursion Pharmaceuticals shares jumped over 16% by midday Wednesday after Morgan Stanley upgraded the stock to ‘Overweight’ and raised its price target to $11, citing strong efficacy for its drug REC-4881.</li></ul>U.S. equities were in the red in Wednesday’s midday trade as investors exercised caution amid a broader decline in artificial intelligence stocks, with Oracle and Broadcom shares declining by nearly 5% each.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.68% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, declined 1.28%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, fell 0.2%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Wednesday’s midday trade:</h2><a href="https://stocktwits.com/symbol/ORCL">Oracle Corp. (ORCL)</a>Oracle shares were down over 5% in Wednesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-s-ai-expansion-hits-snag-as-key-investor-pulls-back-report/cLeO1HSREqa">faced</a> a setback in its AI data center expansion efforts after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.<a href="https://stocktwits.com/symbol/ORCL">ORCL stock</a> is up 8% year-to-date.<a href="https://stocktwits.com/symbol/HUT">Hut 8 Corp. (HUT)</a>Hut 8 shares were up more than 11% in Wednesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hut-shares-soar-over-24-percet-today-whats-the-deal-involving-google-and-anthropic/cLeO1aZREqJ">announced</a> that it is building an AI data center for Anthropic, and that it had signed a 15-year, $7 billion lease with Fluidstack. The company added that the lease would be worth up to $17.7 billion if all renewal options are exercised.<a href="https://stocktwits.com/symbol/HUT">HUT stock</a> is up 100% year-to-date.<a href="https://stocktwits.com/symbol/PCSA">Processa Pharmaceuticals Inc. (PCSA)</a>Processa Pharmaceuticals share price nearly doubled, hovering at gains of 95% in Wednesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-processa-pharmaceuticals-stock-surge-160-today/cLeOVJlREqV">stated</a> that its early Phase 2 trial data showed that its NGC-Cap therapy significantly increases exposure to capecitabine cancer-killing drug metabolites without increasing the severity of side effects compared to standard monotherapy capecitabine therapy.<a href="https://stocktwits.com/symbol/PCSA">PCSA stock</a> is down 73% year-to-date.<a href="https://stocktwits.com/symbol/RXRX">Recursion Pharmaceuticals Inc. (RXRX)</a>Recursion Pharmaceuticals shares were up over 16% in Wednesday’s midday session after Morgan Stanley upgraded the stock to ‘Overweight’ from ‘Neutral’, according to TheFly. The firm also hiked its price target for the RXRX stock to $11 from $10, citing “strong and durable” efficacy in familial adenomatous polyposis from the company's small-molecule drug, REC-4881.<a href="https://stocktwits.com/symbol/RXRX">RXRX stock</a> is down 28% year-to-date.<a href="https://stocktwits.com/symbol/UDMY">Udemy Inc. (UDMY)</a>Udemy shares were up more than 22% in Wednesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cour-udmy-stock-premarket-coursera-udemy-announce-merger/cLeOKUtREq4">announced</a> a merger with Coursera Inc. (COUR), with an implied equity value of the combined entity of approximately $2.5 billion.<a href="https://stocktwits.com/symbol/UDMY">UDMY stock</a> is down 20% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/waller-fed-chair-odds-surge-after-dovish-comments/cLeOjlBREqg">Waller's Odds For Fed Chair Nomination Surge After The Fed Governor's Dovish Comments On Rate Cuts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today

Oracle shares were down over 5% in Wednesday’s midday session after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.

<ul class="summary-bullets"><li>Processa plans to complete enrollment for the formal 20-patient interim analysis by the end of the first quarter of 2026.</li><li>The company’s stock also began trading on a 1-for-25 reverse stock split basis on Wednesday.</li><li>Trading in PCSA shares was halted multiple times today, according to Nasdaq data.</li></ul>Processa Pharmaceuticals Inc. (PCSA) surged over 160% on Wednesday, after the company announced that early Phase 2 data showed that its Next Generation Cancer (NGC) therapy delivered higher levels of cancer-fighting metabolites in patients with advanced or metastatic breast cancer.The company’s stock also began trading on a 1-for-25 reverse stock split basis on Wednesday. Trading in <a href="https://stocktwits.com/symbol/PCSA">PCSA shares</a> was halted multiple times on Wednesday, according to Nasdaq data.<h2 class="st-heading-2">Phase 2 Study Results&nbsp;</h2>Preliminary data from the first 16 of 19 enrolled patients indicated that NGC-Cap significantly increases exposure to capecitabine’s cancer-killing metabolites compared with standard capecitabine monotherapy without increasing the severity of side effects seen with standard treatment. The company believes the balance could improve outcomes for patients with advanced breast cancer.Nineteen patients were randomized to receive either NGC-Cap (150 mg twice daily) or standard Mono-Cap (1,000 mg/m² twice daily). Early safety data from the first 16 patients show higher exposure to cancer-killing metabolites in the NGC-Cap group.While more patients in the NGC-Cap group experienced side effects related to these metabolites, the severity was similar to that in the Mono-Cap group.&nbsp;Processa plans to complete enrollment for the formal 20-patient interim analysis, which will include both safety and efficacy data, by the end of the first quarter of 2026. The company expects to report the interim analysis in early 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’, amid ‘extremely high’ message volumes. PCSA was the top trending ticker on Stocktwits.<figure class="image"><img style="aspect-ratio:922/93;" src="https://news.stocktwits-cdn.com/PCSA_png_df422e4216.webp" alt="PCSA.png" width="922" height="93"><figcaption>PCSA's Sentiment Meter and Message Volumes at 11:30 a.m. ET on Dec. 17, 2025 | Source: Stocktwits</figcaption></figure>One Stocktwits user expects further upside to the stock.<stembedurl>https://stocktwits.com/AJWW316/message/639440673</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/uwm-holdings-to-acquire-two-harbors-investment-in-1-3-b-deal/cLeOjLYREqf">UWM Holdings To Acquire Two Harbors Investment In $1.3B Deal - How Much Of The Combined Company Will UWM Shareholders Own?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Why Did Processa Pharmaceuticals Stock Surge 160% Today?

The company announced that early Phase 2 data showed that its NGC therapy increased cancer-fighting metabolites in patients with advanced breast cancer.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Processa Pharmaceuticals Inc

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.25	--	--	N/A
Q3 '25	-$0.08	--	--	N/A
Q2 '25	-$0.24	-$0.25	-4.17%	MISSED
Q1 '25	-$0.30	--	--	N/A
Q4 '24	-$0.85	--	--	N/A

PCSA
Processa Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest PCSA News

PCSAProcessa Pharmaceuticals Inc